Literature DB >> 8641010

Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation.

A Cittadini1, H Strömer, S E Katz, R Clark, A C Moses, J P Morgan, P S Douglas.   

Abstract

BACKGROUND: Despite their increasing clinical use and recent evidence that growth hormone (GH) and insulin-like growth factor-1 (IGF-1) target the heart, there has been no systematic investigation of the effects of GH and IGF-1 on the cardiovascular system. METHODS AND
RESULTS: Sixty normal but growing adult female rats were randomized to receive 4 weeks of treatment with GH (3.5 mg.kg-1.d-1), IGF-1 (3 mg.kg-1.d-1), a combination of the two, or placebo. Transthoracic echocardiograms were performed at baseline and at 2 weeks and 4 weeks of treatment. After the final echocardiography, rats underwent either closed-chest left ventricular (LV) catheterization or Langendorff perfusion studies. Myocyte diameter and interstitial tissue fraction were assessed by morphometric histology. Echocardiographic and ex vivo data demonstrated a LV hypertrophic response in all three groups of treated animals that was most marked in the GH group, which alone exhibited a concentric growth pattern (relative wall thickness, 0.52 versus 0.42 to 0.44 in the other groups; P < .001). At 4 weeks, cardiac index was significantly higher and total systemic vascular resistance was lower in all groups of treated animals than in control animals (both P < .001), whereas arterial blood pressure did not differ significantly. All indexes of in vivo and in vitro cardiac function were higher in GH- and IGF-1-treated rats than in control animals, whereas combination therapy yielded a blunted effect. Myocyte diameter was increased in all three treated groups without an increase in interstitial tissue.
CONCLUSIONS: Exogenous administration of GH and IGF-1 in the normal adult rat induces a cardiac hypertrophic response without development of significant fibrosis. Cardiac performance is increased both in vivo and in the isolated heart.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641010     DOI: 10.1161/01.cir.93.4.800

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  57 in total

Review 1.  Cytokines and their receptors in cardiovascular diseases--role of gp130 signalling pathway in cardiac myocyte growth and maintenance.

Authors:  K Yamauchi-Takihara; T Kishimoto
Journal:  Int J Exp Pathol       Date:  2000-02       Impact factor: 1.925

2.  Intravenous IGF-I receptor antisense reduces IGF-IR expression and diminishes pressor responses to angiotensin II in conscious normotensive rats.

Authors:  Tien Thuy Nguyen; Paul James White
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

3.  SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway.

Authors:  Antonio Cittadini; Maria Gaia Monti; Guido Iaccarino; Maria Carmina Castiello; Alfonso Baldi; Eduardo Bossone; Salvatore Longobardi; Alberto Maria Marra; Valentina Petrillo; Lavinia Saldamarco; Matthew John During; Luigi Saccà; Gianluigi Condorelli
Journal:  Cardiovasc Res       Date:  2012-08-08       Impact factor: 10.787

4.  A 90-day safety study of genetically modified rice expressing rhIGF-1 protein in C57BL/6J rats.

Authors:  Maoxue Tang; Tingting Xie; Wenke Cheng; Lili Qian; Shulin Yang; Daichang Yang; Wentao Cui; Kui Li
Journal:  Transgenic Res       Date:  2011-09-11       Impact factor: 2.788

5.  Remodeling of atrial ATP-sensitive K⁺ channels in a model of salt-induced elevated blood pressure.

Authors:  Joshua M Lader; Carolina Vasquez; Li Bao; Karen Maass; Jiaxiang Qu; Eirini Kefalogianni; Glenn I Fishman; William A Coetzee; Gregory E Morley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-01       Impact factor: 4.733

Review 6.  Sex differences in myocardial metabolism and cardiac function: an emerging concept.

Authors:  Carin Wittnich; Luke Tan; Jack Wallen; Michael Belanger
Journal:  Pflugers Arch       Date:  2013-02-13       Impact factor: 3.657

7.  The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.

Authors:  Laura De Marinis; Antonio Bianchi; Gherardo Mazziotti; Marco Mettimano; Domenico Milardi; Alessandra Fusco; Vincenzo Cimino; Giulio Maira; Alfredo Pontecorvi; Andrea Giustina
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

8.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

9.  Ghrelin and cardiovascular diseases.

Authors:  Gaigai Zhang; Xinhua Yin; Yongfen Qi; Lakshmana Pendyala; Jack Chen; Dongming Hou; Chaoshu Tang
Journal:  Curr Cardiol Rev       Date:  2010-02

10.  The role of the Frank-Starling law in the transduction of cellular work to whole organ pump function: a computational modeling analysis.

Authors:  Steven A Niederer; Nicolas P Smith
Journal:  PLoS Comput Biol       Date:  2009-04-24       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.